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ABSTRACT
Lung cancer is the leading cause of cancer death in the world. Across all stages
and all types of lung cancer, the overall 5-year survival is less than 15%. Non-small cell
lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. Tumors
from approximately 10-15% of NSCLC patients in the U.S. harbor epidermal growth
factor receptor (EGFR) kinase domain mutation.
Exon 19 deletion mutation and exon 21 substitution mutations are the two most
prevalent mutations in EGFR tyrosine kinase domain. These kinase domain mutations
lock EGFR in a constitutively active conformation, leading to hyper-activation of prosurvival and anti-apoptotic signaling pathways in NSCLC. In addition, NSCLC harboring
the EGFR kinase domain mutations exhibits a typical oncogene addiction model, where
the cells are exquisitely dependent on mutant EGFR for cell survival and proliferation. In
this model, successful inhibition of the oncogene results in oncogene shock; which
promotes cell cycle arrest and/or cell death. Structurally, EGFR with exon 19 deletion
and exon 21 substitution mutations shows higher affinity to small molecule-reversible
EGFR tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib than ATP.
Consequently, the reversible EGFR TKIs preferentially inhibit EGFR tyrosine kinase
activity to promote oncogene shock in the subset of NSCLC with EGFR kinase domain
activating mutations. In the clinic, patients with the EGFR kinase domain mutations
initially respond well to the EGFR inhibitors; however, acquired drug resistance will
mainly emerge after 6-18 months of treatment.
xi

Besides the well-established EGFR TKI resistant mechanisms such as the EGFR
T790M secondary mutation and MET gene amplification, 30% of resistant mechanisms
are still unknown. Systematic genetic and histological analyses of tumor biopsies from
patients show that about half of the patients present an evidence of epithelial to
mesenchymal transition (EMT). EMT is characterized by the loss of epithelial cell
junction marker E-Cadherin and gain of mesenchymal cell marker such as N-Cadherin
and Vimentin. EMT is associated with many cellular changes, however, the molecular
mechanisms by which mesenchymal-like cells attenuate their dependency on EGFR with
kinase domain mutations are still unknown. We hypothesize that the induction of
mesenchymal transition in NSCLC cells harboring EGFR kinase domain mutation
promotes aberrant upregulation of bypass receptor tyrosine kinases (RTKs) or other
oncogenic drivers to replace the oncogenic mutant EGFR.
While this hypothesis was being tested, several groups have demonstrated by
Zhang’s group that receptor tyrosine kinase AXL is upregulated in EGFR-mutant NSCLC
cell lines with acquired resistance to erlotinib with mesenchymal features. It has been
shown that AXL activates downstream pathways to bypass the mutant EGFR
downstream signaling in NSCLC cells with the mesenchymal phenotype. Despite this
finding, we failed to demonstrate that AXL is the oncogenic driver in our mesenchymal
NSCLC models. Instead, we observed overexpression of chemokine receptor CXCR7 in
vitro and NSCLC models of acquired resistance to EGFR TKI with mesenchymal
phenotype. Consequently, we hypothesized that CXCR7 is an oncogenic driver in EGFR
mutant NSCLC cells with acquired resistance to EGFR TKI to offset the activation of
downstream signaling by mutant EGFR. To test this hypothesis, we ectopically
xii

overexpressed V5 tagged CXCR7 in EGFR mutant NSCLC cells. Our studies
demonstrate that ectopically overexpressing CXCR7 in EGFR mutant NSCLC cells is
sufficient to promote EGFR TKI resistance and EMT. Furthermore, we demonstrated
that EGFR TKI resistance induced by ectopic CXCR7 overexpression in mutant EGFR
NSCLC cells is reversible. We also demonstrated that CXCR7 knockdown not only
restored sensitivity to EGFR TKI but also partially reversed mesenchymal phenotype to
epithelial phenotype. In summary, our data suggested CXCR7 as a promising
therapeutic target for preventing or overcoming EGFR TKI resistance in a subset of
EGFR mutant NSCLC patients.

CHAPTER ONE
INTRODUCTION
Overview of lung cancer
Lung cancer is the leading cause of cancer death in the United States (1). About
1.35 million new patients are diagnosed with lung cancer every year (1) and the 5-yearsurvival rate is less than 15% (1). Lung cancer originates in the tissue of lungs or cells
lining the bronchi and cancer cells continually accumulate mutations which promote
aberrant cell growth and proliferation.
Lung cancers are typically divided into two main categories: small cell lung cancer
(SCLC) and non-small cell lung cancer (NSCLC). About 85% to 90% of lung cancers are
NSCLC and 10 percent of cases are SCLC (2). Some patients are diagnosed with a
combined SCLC/NSCLC cancer as well (2). Based on whether the cancer is local or has
spread from the lungs to the lymph nodes or other organs, lung cancer has been defined
as different stages (3). In Stage I, the cancer is located only in the lungs and has not
spread to any lymph nodes. In stage II, the cancer is in the lung and nearby lymph
nodes. In the stage III, cancer is found in the lung and in the lymph nodes in the middle
of the chest, also described as locally advanced disease. Stage IV is the most advanced
stage of lung cancer, and is also described as advanced disease. This is when the
cancer has spread to both lungs, to fluid in the area around the lungs, or metastasized to
another part of the body. The early symptoms like coughing and fatigue are not easily
1
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noticed, even 7-10% of patients with lung cancer are asymptomatic, lung cancer has a
poor prognosis and most people with lung cancer are not diagnosed when the disease is
well advanced.
After the initial diagnosis of NSCLC, it is necessary to determine the patients’ stages
accurately in order to make the right therapeutic decision (3). Treatment of lung cancer
mainly involves surgery, chemotherapy, radiation therapy and more recently targeted
therapy-alone, or in combination (4). Surgery to remove the tumor is the most potentially
curative therapeutic options for the NSCLC in the stage I and early stage II periods.
Surgery in combination with chemotherapy and radiation could also provide great
efficacy than surgery alone and could reduce the chance of recurrence. Because most
lung cancer cannot be completely cured by the current therapy, appropriate palliative
care is also a very important part in the lung cancer treatment (5).
One of the most exciting developments in lung cancer therapy is the introduction
of targeted therapies. Targeted therapies are designed specifically to attack the
abnormal molecules responsible for the specific tumor so that they are considered to be
more effective and have fewer side effects as compared to traditional chemotherapies
(6). The identification of oncogenic drivers that are known to play essential roles in
cancer growth and survival in NSCLC cells is necessary for the efficacy of targeted
therapies. Patients who have advanced lung cancer with certain molecular biomarkers
may benefit from targeted drug alone or in combination with chemotherapy (7). Among
these, epidermal growth factor (EGFR) kinase domain mutations in NSCLC strongly
predict the improved response rate and progression-free survival by EGFR inhibition (6).
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EGFR kinase domain mutant NSCLC
EGFR is a trans-membrane cell surface receptor tyrosine kinase (8). It is a member
of ErbB family of receptors (8). ErbB family is composed of four structurally related
receptor tyrosine kinases: ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4
(HER4). These receptors consist of an extracellular ligand-binding domain, a transmembrane lipophilic domain and an intracellular tyrosine kinase domain. EGFR is
activated by binding of its ligands including epidermal growth factor (EGF) and
transforming growth factor-α (TGF- α) (8). Upon binding by its ligands, EGFR undergoes
conformational changes which promote homo-dimerization with EGFR or heterodimerization with other ERBB family members such as ErbB3. EGFR dimerization
stimulates the auto-phosphorylation of its tyrosine residues in the intracellular domain
through transferring γ-phosphates from adenosine triphosphate (ATP) (9). This
phosphorylations lead to: 1) increased catalytic efficiency and furthering phosphorylation
of other downstream substrates; 2) phosphorylated tyrosine carboxyl-terminals
constitute docking sites and recruit other downstream signaling proteins containing SRC
homology 2 (SH2), protein tyrosine-binding domains (PTB), or other phosphor-tyrosinebinding domains (10, 11) EGFR together with its downstream substrates form signaling
complexes, and subsequently initiate downstream signaling cascades controlling
multiple cellular processes, including phosphatidylinositol 3-kinase (PI3K)/AKT pathway,
Ras/Raf/mitogen-activated protein kinase pathway (MAPK) pathway, which contribute to
cell survival and proliferation (12, 13).
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In 2004, two groups from the Dana-Farber/ Harvard Cancer Center identified
somatic mutations in the tyrosine kinase (TK) domain of EGFR in most NSCLC patients
who respond well to a small molecule EGFR tyrosine kinase inhibitor (TKI) (14, 15). As
EGFR TKI preferentially inhibits mutant EGFR, the efficacy of EGFR TKI is profound in
NSCLC tumors that express mutant EGFR but not in normal cells that express wild type
EGFR. EGFR kinase domain mutations are present in approximately 30-35 percent of
cases in East Asian NSCLC patients and 10 percent of cases in Caucasian NSCLC
patients, especially non-smoking young Asian female patients (16, 17), and are more
associated with adenocarcinomas with bronchioalveolar features (18). The most
prevalent mutations in the EGFR tyrosine kinase domain are located within EGFR exon
18-21, which are around the ATP-binding pocket of enzyme (18) . 45 percent of the
cases are exon 19 deletion, amino-acids between residues 747-750 of EGFR
polypeptide. L858R point substitution mutation in exon 21 also comprises approximately
40-45 percent of EGFR mutations. Nucleotide substitution in exon 18 or exon 20
insertion individually accounts for 5 percent of EGFR mutations (18). Kinase domain
mutations increase the kinase activity of EGFR, leading to hyper-activation of PI3K and
MAPK signaling pathways and consequently confer oncogenic effects (14, 18).
Therefore, cancer cells, which harbor EGFR kinase domain mutations become addicted
to EGFR signaling for their survival and proliferation. In addition, mutant EGFR changes
its kinase domain structure, decreases its affinity to ATP and increases its affinity for
small molecule EGFR TKI such as gefitinib (Iressa) and erlotinib (Tarceva) (15). EGFR
TKI competes with ATP for binding to the catalytic binding site (19) . In the clinic, NSCLC
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patients harboring EGFR kinase domain mutations are associated with increased
sensitivity to EGFR TKI. One of the major effects of EGFR TKI in sensitive EGFR-mutant
NSCLC cells is the induction of intrinsic apoptosis pathways (20, 21). PI3K and MAPK
signaling pathways have been shown to cooperate to promote cell survival and
proliferation on NSCLC (22). EGFR TKI inhibits both PI3K and MAPK pathways and kills
EGFR addicted NSCLC. MAPK inhibition after EGFR TKI treatment leads to rapidly
increased activity of proapoptotic protein BIM in EGFR mutant NSCLC by increasing the
production and dephosphorylation of BIM (20, 21). PI3K inhibition after gefitinib
treatment leads to downregulation of anti-apoptotic protein myeloid leukemia cell
differentiation 1 (MCL1) (23). The upregulation of BIM cooperates with the
downregulation of MCL1 to promote cell death. Despite the initial response to EGFR
TKI, the development of resistance inevitably occurs after 6-18 months treatment (24).
Resistance to EGFR-target therapy
Primary resistance: Most EGFR kinase domain mutations confer sensitivity to
EGFR TKI; however, some EGFR kinase domain mutations predict the primary
resistance to EGFR TKI. There are insertions or duplications mutations that occur in
exon 20 in EGFR gene, resulting in amino acid insertion between D770 and N771 or
substitution in amino acid position 771, render the receptor 100-fold less sensitive to
gefitinib or erlotinib as compared to tumors harboring the exon 21 substitution mutations
or exon 19 deletions in EGFR (25, 26). Although in most cases, exon 20 T790M
mutations are associated with acquired resistance to EGFR TKI, presence of T790M
also links to the primary resistant mechanism (27).
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NSCLC tumor harboring EGFR mutation could be insensitive to EGFR TKI
because of the presence of other genetic alterations that co-occur with EGFR mutations.
EGFR downstream signaling pathways, PI3K and MAPK, are critical for cell survival and
proliferation in EGFR mutant NSCLC (22). Tumor cells sensitive to EGFR TKI are
characterized by remarkable down-regulation of AKT phosphorylation (28, 29).
Consequently, activating mutation in phosphaticylinositol-4,5-biphophate 3-kinase,
catalytic subunit alpha (PIK3CA) is found to rescue the cells from sensitivity to EGFR
TKI (30). Also, loss of phosphatase and tensin homologue (PTEN) expression, which
indirectly regulate the activation of AKT, correlates with decreased sensitivity of EGFR
mutant NSCLC to EGFR TKI (31). Insulin-like growth factor receptor 1 (IGFR1), has
been implicated as a potential resistant mechanism through crosstalk with EGFR to
continually activate PI3K signaling pathway in EGFR overexpressed glioblastoma cells
(32). Recently, Bivona et al. identified the hyperactivation of NFkB pathway as a new
mechanism of primary resistance to gefitinib or erlotinib (33) . This group observed 18
genes that are involved in NFkB signaling were directly or indirectly amplified in EGFR
TKI resistant EGFR mutant NSCLC cells. Activation of NF-kB through overexpression of
c-FLIP or IKK, or silencing of IkB, rescued EGFR-mutant lung tumor cells from EGFR
TKI treatment. On the contrary, inhibition of FAS and several components of the NF-kB
pathway specifically enhanced EGFR TKI induced cell death in EGFR-mutant lung
cancer (33).
It has been increasingly clear that cancer cells that express the canonical
mesenchymal markers have intrinsic resistance to EGFR TKI (34, 35). Independent
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research groups have processed gene expression and proteomic profiles in an attempt
to identify epithelial and mesenchymal cell biomarkers that related to sensitivity to EGFR
TKI (34, 35). They found that the cell lines which were sensitive to the EGFR inhibition
expressed the canonical epithelial markers and displayed the typical epithelial
phenotype. On the contrary, cell lines which were resistant to EGFR inhibition expressed
the canonical mesenchymal cell markers and displayed the typical mesenchymal
phenotype (34, 35). In addition, restoration of the canonical epithelial cell marker ECadherin increases the sensitivity to EGFR TKI in NSCLC cell lines (36).
Acquired Resistance: Although NSCLC patients harboring EGFR mutations
respond well to EGFR TKI, the drug resistance mainly develops within 6-18 months of
treatment (24). The emergence of acquired resistance to EGFR TKIs greatly limits the
efficacy of EGFR TKI to prolong patient survival (18). In order to overcome the acquired
EGFR TKI resistance, it becomes more important to study the molecular and cellular
mechanisms underlying the acquired EGFR TKI resistance.
About 50 percent of the acquired resistant cases are attributed to the emergence
of the second-site gatekeeper mutation in EGFR exon 20, which is a change of a
threonine to a methionine in amino acid position 790 (T790M) (37). The mechanism by
which the T790M mutation confers resistance to gefitinib and erlotinib has been
demonstrated that T790M secondary mutation restores the affinity of EGFR to ATP
again, as a result, restore enzymatic activity of EGFR (38). T790M secondary mutation
reduces the therapeutic effect of gefitinib or erlotinib to the patients.
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MET, which is a transmembrane receptor tyrosine kinase encoded by an
oncogene, has been observed to be amplified in up to 20 percent patients who develop
EGFR TKI resistance after several month treatments (39). MET amplification contributes
to EGFR TKI resistance through a mechanism called ‘receptor kinase switch’ and it can
occur independently or can coexist with EGFR T790M mutation among EGFR TKI
secondary resistance (40). MET dimerization and activation can occur in either liganddependent or ligand-independent way. MET ligand was identified as hepatocyte growth
factor (HGF), also named as scatter factor (SF) (39, 41). Published studies have verified
that EGFR mutant NSCLC cells activate the PI3K pathway through dimerization of
EGFR with ERBB3 and down-regulation of PI3K signaling is the marker of sensitivity to
gefitinib or erlotinib (42, 43). MET amplification replaces the function of EGFR sustaining
the activation of PI3K signaling by coupling to ERBB3 in gefitinib resistant EGFR mutant
NSCLC cells (39). In addition, the MET ligand HGF has been reported to induce gefitinib
resistance by independently activating PI3K signaling pathway (41). Different from the
MET receptor amplification that promotes EGFR TKI resistance in EGFR mutant NSCLC
cells through coupling to ERBB3 and activating ERBB3/PI3K axis, HGF induces drug
resistance through activating MET/PI3K signaling axis (41). MET amplification was also
observed, although rare, in EGFR mutant NSCLC patients before gefitinib treatment and
associated with EGFR TKI resistance (44).
Among all EGFR TKI resistant mechanisms in EGFR mutant NSCLC, EGFR
T790M secondary mutation and MET amplification mutations account for 60-65 percent
of all cases. Tumors from remaining EGFR TKI resistant cases neither harbor secondary
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T790M mutation nor MET amplification. Sequist et al. performed a comprehensive
genetic and histological analysis of 37 NSCLC patients before and after EGFR TKI
treatment (45). All patients either had EGFR exon 19 deletion mutations or exon 21
L858R substitution mutations and initially respond to EGFR TKI, but subsequently
developed drug resistance. Besides T790M secondary mutations and MET amplification,
5 percent of patients develop mutations in PIK3CA (45). Sequist et al. also found
phenotypic transformation from NSCLC to SCLC leads to EGFR TKI resistance in 14
percent of patients with acquired resistance (45). The study reported that about 30% of
the resistant mechanisms remain elusive. Among these unknown resistant mechanisms,
about half of the NSCLC patients present evidence of epithelial to mesenchymal
transition (EMT).
Overview of EMT
EMT is an evolutionarily conserved process by which cells undergo morphological
changes from the epithelial polarized cell-cell adhesion phenotype to a more migratory
invasive and fibroblast-like mesenchymal phenotype (46). The molecular markers of
EMT are associated with transcriptional reprogramming such as decreased expression
of proteins involved in cell junction such as E-Cadherin, and increased expression of
mesenchymal cell markers such as Vimentin and N-Cadherin (47). EMT was first
recognized as a feature of embryogenesis (46). Epithelial and mesenchymal cells are
different not only in phenotype but also in functions. During embryonic development,
differentiated epithelial cells could lose their cell-cell junction and basolateral polarity and
undergo morphogenetic changes to migratory invasive mesenchymal cells, referred to
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as EMT. After reaching specific sites, mesenchymal cells are recruited and differentiate
to epithelial tissue and organs through mesenchymal to epithelial transition (46).
Reduced E-Cadherin expression disrupts the cell-cell adherence junction and
polarized cell shape, so that the loss of E-Cadherin is considered to be an essential
biomarker of EMT (48, 49). E-Cadherin loss has been implicated with activation of βcatenin and its nuclear translocation (50, 51). β-catenin is a critical intracellular protein
associated with the E-Cadherin cytoplasmic tail and has been much reported to play an
important role in the induction of EMT (51) . The loss of E-Cadherin result in the
dephosphorylating and activating of β-catenin molecule that is otherwise phosphorylated
and targeted for ubiquitylation and degradation. Activated β–catenin forms a nuclearlocalized transcriptional complex with other transcription factors, including Snail, ZEB1,
and Twist, and promotes complex gene expression changes that contribute to the EMT
process (51).
Several extracellular signals such as transforming growth factor-β (TGF-β)
signaling (52), Wnt signaling (53), Notch pathway (53), receptor tyrosine kinases (53, 54)
also trigger EMT by complex signaling networks. The consequences of these signaling
are upregulation of transcription factors, including Snail, Slug, and Twist which have high
affinity for the E-box elements in the E-Cadherin promoter and inhibit E-Cadherin
expression (55).
EMT and acquired EGFR TKI resistance
Much effort has been focused on understanding how EMT regulates the
progression of NSCLC cells to be more invasive and metastatic; however, relatively less
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effort has been made on elucidating how EMT promotes resistance to EGFR targettherapies in NSCLC harboring mutant EGFR.
EMT has been shown to promote acquired resistant mechanism to EGFR TKI in
the NSCLC cell line models harboring EGFR kinase domain mutations. EMT was
observed in about 15 percent cases among post-gefitinib treatment tumors (45). Suda et
al. reported that chronic exposure of EGFR mutant HCC4006 cells to increasing
concentration of erlotinib induced epithelial to mesenchymal transition and confer the
cells resistance to erlotinib (56). Additionally, restoration of canonical epithelial cell
marker E-Cadherin using histone deacetylase inhibitor MS-275 restored the sensitivity of
erlotinib in the HCC4006 cells with acquired resistance to erlotinib (56). EMT is
associated with many cellular changes; however, the molecular mechanisms by which
mesenchymal-like cells attenuate their dependency on EGFR for survival and
proliferation are still unknown. One explanation is that EMT promotes the cells to acquire
alternative pathways so that the survival of the cells is independent of EGFR signaling.
As a result, cells with a mesenchymal phenotype are resistant to EGFR TKI (57). It has
been shown that the cancer cells can shift the cellular dependence in the response of
EGFR TKI treatment (42, 58). PI3K and MAPK signaling pathways are critical for the
survival and proliferation in NSCLC cells with mesenchymal phenotype (34), therefore,
the molecular determinants of activation of PI3K and MAPK pathways which promote
cellular resistance to EGFR TKI induced apoptosis have been actively investigated.
Involvement of AXL in EGFR TKI resistance in EGFR mutant NSCLC with EMT
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AXL is a tyrosine phosphorylated 140kDa protein which belongs to a member of
Tyro3-Axl-Mer (TAM) receptor tyrosine kinase (RTK) subfamily (59) and was first
isolated from patients with chronic myelogenous leukemia (CML) and chronic myeloproliferative disorder (60). Like all RTKs, AXL consists of an extracellular domain, a
transmembrane domain and a cytoplasmic domain with kinase activity. The extracellular
domain of AXL is composed of a combination of two immunoglobin-like (Ig) motifs and
dual fibronectin type III (FN III) repeats (59). AXL transduces signals by binding to its
specific ligands. Protein S and vitamin K-dependent protein growth arrest–specific 6
(Gas6) are ligands for AXL, whereas only the Gas6 is confirmed as high affinity to AXL
(61, 62). Like other RTKs, conventional activation of the receptor involves ligand binding
to the extracellular domain. Ligand binding induces receptor dimerization and transphosphorylates tyrosine residues in the cytoplasmic kinase domain (63). Phosphorylated
tyrosine recruits other downstream signaling proteins binding to it through their phospho
tyrosine-binding SH2 domain. The primary signaling downstream of AXL appears to be
the PI3K and MAPK signaling pathways (64, 65). AXL dimerization and activation has
been shown to occur in a ligand-independent manner- homophilic binding of extracellular
domains between neighboring cells (66) and AXL overexpression (67). AXL activation
and signaling have been linked to multiple cellular responses, including cell survival,
proliferation, adhesion and cytokine production, as well as immune-regulatory (68).
The role of AXL in cancer biology has attracted attention. AXL has been implicated
to be upregulated in variety of cancers including breast (69), gastric (70), prostate (71),
lung (72). Overexpression of AXL has been reported as relative to increased tumor
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growth rate, metastasis and poorer prognosis (72, 73). Recently, AXL has also been
considered as a potential candidate for overcoming EGFR TKI resistance in EGFR
mutant NSCLC cells through activation of PI3K and MAPK signaling by its
overexpression or binding to its ligand GAS6 (74). AXL activation enables the cells to
bypass the mutant EGFR signaling in a manner similar to the resistant mechanism
mediated by MET amplification in mutant EGFR NSCLC. The phenomenon is termed as
‘receptor tyrosine kinase switch’. Zhang et al. group has developed tumor model with
acquired resistance to erlotinib in vitro using HCC827 NSCLC cell line with EGFR kinase
domain exon 19 deletion mutation and in vivo model with HCC827-derived xenograft
tumors (74). They found that AXL was highly overexpressed in the EGFR TKI resistant
groups with mesenchymal phenotype, as compared to the vehicle-treated tumors.
Inhibition of AXL by chemical or genetic methods restored erlotinib sensitivity in HCC827
cells. They validated the finding in matched pre- and post-EGFR TKI treatment clinical
specimens from 35 NSCLC patients with either exon 19 deletion or exon 21 point
mutation of EGFR and concluded that AXL or GAS6 overexpression was associated with
resistance to EGFR TKI (74). Furthermore, AXL promotes the expression of antiapoptotic BCL-2 family members and to inhibit the expression of pro-apoptotic BAD
family proteins which are responsible for the resistance of target therapy (75).
In addition to its role as an oncogenic driver in the EGFR TKI resistant NSCLC
cells, AXL is also associated with the process of EMT (76). In pancreatic cancer,
Koorastra et al. observed that AXL expression is necessary to maintain EMT
transcription factors expression, such as Snail, Slug and Twist (73). AXL is also
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demonstrated as a downstream effector of the EMT program in many tumor types since
the activation of EMT program promotes the upregulation of AXL and downstream
signaling (53, 76, 77). A recent published paper from Asiedu group revealed a novel
function of AXL in acting upstream to induce EMT in normal epithelial breast cancer cells
(78). Moreover, it has been shown that downregulation of AXL promotes mesenchymal
to epithelial transition in mesenchymal breast cells (78).
Byers et al. performed a comprehensive gene expression signature analysis of 76gene EMT signatures and demonstrated that epithelial and mesenchymal phenotypes
determine EGFR TKI sensitivity in NSCLC harboring mutant EGFR (79). Among the
genes which are upregulated in the mesenchymal groups, they found high level of AXL.
AXL overexpression in mesenchymal like NSCLC cells was further confirmed by
proteomics approach and reverse-phase protein array (RPPA). The author then
validated the correlations between EMT and poor erlotinib response. NSCLC patients
were subjected to Biomarker-integrated Approaches of Targeted Therapy for Lung
Cancer Elimination (BATTLE-1) trail. Patients with an EMT signature including increased
level of AXL and its ligand GAS6 predicted poor clinical outcome to erlotinib as compare
to the patients without EMT signature. Furthermore, in vitro, they found AXL inhibition
together with EGFR inhibition had a striking synergistic effect compare to EGFR
inhibition alone in AXL overexpressing mesenchymal NSCLC cells.
Collectively, these data suggest that AXL / GAS6 and its downstream signaling
pathways serve as a potential mechanism associated with EGFR TKI resistance in
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EGFR mutant NSCLC with mesenchymal phenotype. Detection and targeted therapy to
AXL may be a new avenue to circumvent this resistance.
Chemokine receptor CXCR7 and its potential role in acquired EGFR TKI resistance
with epithelial to mesenchymal transition
C-X-C chemokine receptor type 7 (CXCR-7), formerly known as RDC1, was first
cloned from a dog thyroid cloned DNA (cDNA) library (80). CXCR7 is a member of the
G-protein-coupled receptor family and has the canonical structural features of GPCRs
with a seven-transmembrane helices connected by extracellular and intracellular loops.
It is known that chemokine ligands CXCL12 (or stromal-derived growth factor-1, SDF1)
and CXCL11 (or IFN-inducible T cell α-chemoattractant, I-TAC) transmit their signals by
binding to the receptor (81, 82). Expression of CXCR7 plays a role in cardiac
development as well as with tumor growth and progression (82, 83).
Unlike classical G-protein coupled receptors which are initiated by binding with
heterotrimeric G proteins, CXCR7 is activated by association with β-arrestin (84). In the
absence of ligand, CXCR7 constitutively interacts with Gαi, but does not activate them.
Ligand binding to CXCR7 recruits G protein receptor kinase (GRK) which in turn
phosphorylates and activates the receptor. Phosphorylated receptor then increases its
affinity to β-arrestin and results in activation of MAPK and PI3K signaling pathways (84).
The process of CXCR7 activation is a model of ligand initiated, G-protein-independent,
β-arrestin-dependent signaling pathways (84-86).
Signal transduction initiated by CXCR7 is controlled at the membrane by the
process of CXCR7 trafficking. The level of receptor expression at the cell membrane
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directly affects the magnitude of the cellular response initiated by the ligand binding (87).
Apart from the β-arrestin-dependent manner, reversible ubiquitination plays an essential
role in the regulatory mechanism of CXCR7 internalization (87). Ubiqutination is a posttranslational process that results in the covalent bond of the small protein ubiqutin to a
lysine in the modified protein with profound consequences for endocytic cycles of the
receptor (88). This modification of ubiquitination is mediated by three distinct enzymes.
Ubiquitin is processed by an E1-activating enzyme, forming a thioester bond with
ubiquitin that is required for transfer to E2-conjugating enzymes, and E3 ubiquitin ligases
facilitate the covalent attachment of ubiquitin to substrate proteins (88). A recent study
suggests that CXCR7 is constitutively ubiquitinated and such ubiquitination is important
in modification of receptor trafficking (87). CXCR7 ubiquitination is necessary for cell
surface delivery of the receptor. The absence of this ubiquitination leads to a
constitutively internalized receptor. Upon ligand stimulation, CXCR7 phosphorylation at
serine/threonine in the C-terminus promotes β-arrestin recruitment. β-arrestin interacts
with a de-ubiquitinating enzyme (DUB) causing CXCR7 de-ubiquitination and
endocytosis. On the contrary, disassociation of β-arrestin and interacting proteins would
render the receptor to undergo ubiquitination and ubiquitinated receptors are recycled
back to the cell surface (87).
Accumulating evidence suggests that CXCR7 plays an essential role in the
survival, proliferation, metastasis of tumor cell lines including breast, lung, glioma (82,
89, 90). Thus, CXCR7 has attracted more and more attention in the cancer research
field as a potential pharmacological target for cancer therapy. Higher CXCR7 expression
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is observed in neoplastically transformed cells as compared to their non-transformed
control group supporting the notion that CXCR7 is important during tumorogensis (82). It
is also verified that CXCR7 signaling increased growth rate of sarcoma cells in nude
mice (91). In addition, higher expression of CXCR7 in NSCLC and prostate cancer cells
show a positive correlation in tumor metastatic potential and development (92, 93). It is
reported that CXCR7-transduced murine human breast or lung cancer cell lines grow
larger tumors in immunodeficient mice, wherase decreasing the expression level of
CXCR7 using siRNA shrink the lung tumor size in the vivo study (89). The roles of
CXCR7 in different types of tumor cells are not entirely consistent. For example, Burns
et al. demonstrated that CXCR7 was remarkably overexpressed in breast cancer cell
line MDA-MB-435a and it was required to inhibit apoptosis rather than increasing
proliferation in the cells (82) , whereas Meijer et al. reported CXCR7 played an important
role in cell proliferation in mouse colon and pancreatic cancer cells (94).
In addition, the involvement of CXCR7 in neoangiogensis and formation of the
tumor vasculature has been postulated since higher expression of CXCR7 has been
found in breast cancer-related blood vessels compared to the blood vessel in normal
breast tissue (89). CXCR7 overexpression has also been observed in blood vessels of
other clinical carcinoma biopsy samples such as lung, kidney, prostate (95, 96).
Moreover, CXCR7 overexpression in prostate cancer correlates with the increased
production of vascular endothelial growth factor (VEGF) and IL-8 which have been
shown to be important factors involved in the development of tumor blood supply in the
progression of solid tumor (95).
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Of note, recent studies proposed that high expression of CXCR7 correlates with
tumor metastatic potentials. One prostate cancer study from Wang J et al. suggested
that high expression of CXCR7 predicted highly aggressive metastasis (95). They found
CXCR7 expression regulated CD44 antigen (CD44) as well as cadherin 11 (CDH11)
levels. CD44 was found to play a critical role for metastatic behavior of tumor cells
including pancreatic cancer (97), prostate cancer (98), head and neck cancer (99).
Similarly, expression of CDH11 was also regulated by CXCR7. CDH11 was identified to
be expressed in mesenchymal cells and in a subset of highly invasive cell lines and
aggressive breast carcinomas (100). In the study, they observed that expression level of
CXCR7 also regulated TGF-β expression. TGF-β is reported to induce mesenchymal
transition in epithelial cells (101), and exposure to TGF-β is associated with reduced
sensitivity to gefitinib in NSCLC (102). Another research group reported that higher
expression of CXCR7 was found in early and metastatic recurrence in pathological stage
I NSCLC (92). Moreover, the level of CXCR7 is found to be significantly higher in the
highly metastatic hepatocellular carcinoma cells and inhibition of CXCR7 by siRNA
remarkably reduced tumor proliferation and metastatic invasion (103).
In conclusion, all the evidence demonstrate the importance of CXCR7 in cell
signaling pathways and cancer metastatic behavior and also raise the exciting possibility
that CXCR7 potentially facilitates EGFR TKI resistance in EGFR mutant NSCLC with
mesenchymal phenotype.

CHAPTER TWO
MATERIALS AND METHODS
Cell lines: HCC827, HCC4006, NCI-H1975 cell lines were obtained from the American
Type Culture Collection (ATCC) and were maintained in RPMI-1640 growth media (Life
Technologies, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS) (Life
Technologies, Carlsbad, CA), 1X anti-biotic/anti-mycotic agent (AB/AM) (Life
Technologies, Carlsbad, CA). HCC4006, NCI-H1975 cell lines were maintained in RPMI1640 supplemented with 10% FBS, 1X AB/AM. 293LTV cells were obtained from Cell
Biolabs (San Diego, CA) and cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Life Technologies, Carlsbad, CA) supplemented with 10% FBS and 1X AB/AM. Cells
were cultured at 37°C in a humidified incubator of 5% CO2. All clones generated using
HCC827 cells used in the experiments were authenticated by short tandem repeat (STR)
profiling.
Lentiviral package and production: For virus packaging, the 2.5X 105 293LTV cells
were transfected with 4 μg cDNA cloned in pEXP304-blasticidin vectors or shRNA
sequence cloned in pLKO.1-puromycin vectors together with 4 μg Δ8.2 and 0.6 μg
VSVG lentiviral packaging vectors using 14 μl TransIT-LT1 transfection reagent (MIRUS,
Madison, WI). Transfection mixture was prepared in the proper volume of optiMEM (Life
Technologies, Carlsbad, CA) to make up the total volume to 250 μl. After incubated for
20 minutes added to the cells suspended in RPMI-1640 supplemented with 10% FBS
without AB/AM and the cells were incubated in the transfection mix for 24 hours. 24
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hours post transfection, culture media was replaced with virus production media that is
made of DMEM supplement with 10% FBS, 0.2 g/ml BSA, 1X AB/AM. The supernatant
was harvested 72 and 96 hours post-transfection and the viral supernatant was filtered
using Nalgene Syringe Filter 0.45μm (Thermo Scientific, Hanover Park, IL) and stored in
4°C or -80°C until use.
Target gene knockdown using lentiviral pLKO.1shRNA vector: Bacterial stock of
short hairpin RNA (shRNA) clones in pLKO.1 designed by The RNA Consortium
(MIT/Harvard Broad Institute, Cambridge, MA) were purchased from Open Biosystem
(Pittsburgh, PA) or Sigma (St. Louis, MO). In the shRNA experiments, lentiviral encoding
shRNA was packaged in 293LTV cells as described above. Target NSCLC cells were
transduced at least twice with viral supernatants. Cells containing the target expression
were selected with 5 µg/ml puromycin after infection.
Generation of HCC827 cells stably overexpressing shRNA against Non-Target/
EGFR/ CDH1: HCC827 cells with stably expressing shRNA against non-target (NT),
EGFR and CDH1 cells were generated by transducing exponentially growing HCC827
cells with lentivirus coding for shRNA against NT, EGFR and CDH1, respectively.
Following infection, the cells were subjected to the antibiotic selection to ensure the
expression of shRNA against target. The cells were cultured in RPMI-1640
supplemented with 5% FBS, 1X AB/AM and 5 µg/ml puromycin. Mass culture was
established for HCC827 stably overexpressing shRNA against NT sequence. Western
blot was performed using antibody against EGFR or CDH1 to ensure that there is no
deletion of EGFR or CDH1 in the mass culture. For the generation of HCC827 cells
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stably expressing shRNA against EGFR or CDH1, single clones were established
following puromycin selection. Single clones were screened for knockdown efficiency
and clone with best EGFR or CDH1 knockdown were used for experiments.
Generation of HCC827 or NCI-H1975 cells stably overexpressing GFP or LacZ or
CXCR7: Exponentially growing HCC827 cells or NCI-1975 cells were seeded on 60x 15
mm dishes at the density of 6x105 cells and allowed to adhere to the plate overnight. The
cells were then transduced for overnight with lentivirus coding for GFP or LacZ, CXCR7
tagged with V5 tag. This process was repeated three times to ensure that the cells
express the genes. HCC827 or NCI-H1975 cells were then subjected to antibiotic
selection with 20 µg/ml blasticidin. Following the selection, mass culture was established
and the expression of LacZ-V5 and CXCR7-V5 were confirmed with Western blot using
antibodies against V5 tag. Ectopic CXCR7-V5 expression is also confirmed with Western
blot using antibodies against CXCR7. The expression of GFP was confirmed using
EVOS-XL fluorescent microscope.
Lentiviral knockdown of CXCR7 in HCC827 cells ectopically overexpressing
CXCR7: HCC827 cells ectopically overexpressing GFP or CXCR7-V5 were grown in
RPMI-1640 supplemented with 5% FBS, 1X AB/AM and 20 µg/ml blasticidin and were
transduced with lentivirus coding for NT shRNA or CXCR7 shRNA. To ensure
knockdown of the targets, the cells were transduced twice. The cells were then
subjected to antibiotic selection with 20 µg/ml blasticidin and 5 µg/ml puromycin. Mass
culture resistant to both blasticidin and puromycin were generated and knockdown
efficiency was confirmed with Western blot using antibody against V5 or CXCR7. The
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cells were maintained in RPMI-1640 supplemented with 5% FBS, 1X AB/AM, 20 µg/ml
blasticidin and 5 µg/ml puromycin.
Drugs: Gefitinib and XL-184 (ChemieTek, Indianapolis, IN) were prepared as a 10mM
stock solution in dimethyl sulfoxide (DMSO) and stored in -20°C until use and used at
concentrations ranging from 0.001 to 10 µM.
Cell viability assay: Cells were seeded at a density ranging from 2000-3000 depending
on cell lines per well on 96-well plates and allowed to adhere overnight in the
appropriate growth media mentioned in the cell line section. Subsequently, cells were
treated with increasing concentrations of drugs serially diluted in growth media for 72
hours, and subjected to cell viability assay with Cell Counting Kit-8 (CCK-8) (Dojindo
Molecular Technology, Inc., Rockville, Maryland). Samples were prepared in duplicates.
After the incubation with CCK-8, plates were read on a microplate reader (Bio-Tek,
Winooski, VT). The data were collected and analyzed by the graphpad prism version
5.00 for Windows (GraphPad Software, La Jolla, CA). The results were expressed as
mean viable cells relatively to RPMI-1640 alone (considered as 100% viability) ± SD.
Western blot: The cells were cultured in the tissue culture plates (BD Falcon, San Jose,
CA), allowed to attach overnight. To assess cell signaling, cells were incubated with the
indicated drug concentration or control DMSO and incubated for 24 or 48 hours. The
cells were washed twice with ice-cold 1X modified DPBS with Calcium and Magnesium
and whole-cell lysates were prepared in the lysis buffer containing 20 mM Tris-HCl
(PH7.5), 15 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1µg/ml leupeptin (Cell
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Signaling Technology, Danvers, MA) supplemented with Halt protease and phosphatase
single-use inhibitor cocktail (Pierce, Rockford, IL). To detect CXCR7, we use lysis buffer
containing 62.5 mM Tris-HCL (pH 6.8), 2% SDS, 10% sucrose, supplemented with halt
protease and phosphatase single-use inhibitor cocktail (Pierce, Rockford, IL). Protein
concentrations were determined using Pierce bicinchoninic acid (BCA) protein assay kit
(Pierce, Rockford, IL) and equivalent amount of protein were subjected to mini-protean
TGX 4-20% gradient gels (Bio-Rad, Hercules, CA) and blot with different antibodies
(Table 1.) Blot detection was done by ECL Western Blot Detection Reagents
(PerkinElmer, Waltham, MA). After Western blot, films were developed and scanned.
Loading were corrected with ImageJ software (NIH Image, Bethesda, MD).
Table 1. Antibody list

Phospho-RTK array analysis: Proteome Profiler human phospho-RTK antibody array
(R&D Systems, Minneapolis, MN) was used according to the manufacturer’s instructions
to measure the relative level of tyrosine phosphorylation of 42 distinct receptor tyrosine
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kinases (RTKs). Cells were seeded in 10x20mm dishes at a density of 2.0x106 and the
cells were allowed to adhere to the plates overnight. Cells were then treated with either
control DMSO or 1 µM gefitinib for 24 hours. The cells lysates were prepared by
solubilizing the cells at 1x107 cells/ ml in RTK array specific lysis buffer (R&D Systems,
Minneapolis, MN). 100 µg of fresh protein lysates were incubated with array membranes
overnight at 4°C. The membranes were then incubated with anti-phosphotyrosine-HRP
antibody for 2 hours at room temperature to detect tyrosine phosphorylated RTKs.
Western blot was done by ECL Western Blotting Detection Reagents (PerkinElmer,
Waltham, MA). Then the membrane was exposed to X-ray film to detect activated
receptors.
siRNA transfection: Silencer validated small interfering RNAs (siRNAs) for AXL,
CXCR7 and control NT were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). 2.0x105 cells were seeded into 6-well plates and allowed to attach overnight.
Concentration of 3.5 μl of 10 μM siRNA and 6 µl of TransIT- siQUEST transfection
reagent (MIRUS, Madison, WI) were each mixed with 250 µl of optiMEM medium.
Solution was incubated for 20 minutes in the room temperature before added to the
cells. siRNA mediated knockdown efficiency was measured by Western blot after 96
hours of transfection.
Apoptosis AnnexinV Assay: 3x105 cells were seeded in duplicates in the 6-well tissue
culture plates, allowed attaching to the plate overnight. To assess drug effect to the cell
apoptosis, Annexin V staining was proceeding after 48 hours drug treatment. Annexin V
binding buffer (Cell Signaling Technology, Danvers, MA) was used at the concentration
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range from 1x105 to 1x106 cells/ml after washing with ice-cold growth media. 96 µl of cell
suspension was transferred to a 5 ml flow tube, stained with AnnexinV/FITC (Cell
Signaling Technology, Danvers, MA) and PI (Cell Signaling Technology, Danvers, MA)
and incubated on ice in the dark for 10 minutes. The stained cell suspension was then
subjected to the Fluorescently Activated Cell Sorting (FACS) analysis using BD canto II
machine (BD Biosciences, San Jose, CA). Results were analyzed by using Flowjo
software (Tree Star Inc. Ashland, OR).
qRT-PCR: To validate changes in gene expression identified in gene expression
profiling, RT-PCR was performed to quantify the amount of target mRNA. Total RNA
was isolated using RNeasy Mini Kit (Qiagen, Germantown, MA) according to the
manufacturer’s instructions. The quantity of RNA and purity were determined using
NanoDrop ND-1000 (Thermo Scientific, Hanover Park, IL) and Qubit 2.0 Flurometer
(Invitrogen, Carlsbad, CA). cDNA was synthesized from 500 ng total RNA using high
capacity cDNA reverse transcription kit (Applied Biosystems, Forster City, CA). For qRTPCR analysis of RNA expression, the RT- PCR was performed in a 20 µl reaction
volume containing TaqMan Universal master mix (Applied Biosystems, Forster City, CA).
Cycling conditions were set as 50°C 2 minutes- 95°C 10 minutes- 95°C 15 minutes60°C 1min. RT-qPCR was performed and the values were obtained of the threshold
cycle for the CXCR7 and normalized using the housekeeping gene GusB.
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Table 2. CXCR7 Primers list

CHAPTER THREE
RESULTS
EGFR or E-Cadherin depletion by lentiviral shRNA in HCC827 cells induces
epithelial to mesenchymal transition. HCC827 NSCLC cells overexpress EGFR with
the exon 19 deletion mutation and are exquisitely sensitive to EGFR TKI (14). Usually,
acquired resistance to EGFR TKI is studied by exposing HCC827 cells to increasing
doses of EGFR TKI for up to 6 months in tissue culture system (37). The problem of this
approach is that off-target effects of EGFR TKI might contribute to the development of
acquired resistance to EGFR TKI. To eliminate the possibility of off-target effects, Dr.
Shimamura stably knocked down EGFR using lentiviral shRNA against EGFR in
HCC827 cells (HCC827 shEGFR) and acquired resistant clones with mesenchymal
phenotype were isolated (acquired resistant clone with MET amplification was also
observed, data not shown). Robert Weinberg and his colleagues have demonstrated that
the depletion of E-Cadherin in breast epithelial cells is sufficient to promote
mesenchymal transition (51). Motivated by this finding and to investigate if inducing a
mesenchymal phenotype in HCC827 cells is sufficient to confer EGFR TKI resistance in
HCC827 cells, HCC827 cells were transduced with lentivirus coding for shRNA against
E-Cadherin (CDH1) and stable clones were isolated by Dr. Shimamura. HCC827 with
constitutive E-Cadherin knockdown cells (HCC827 shCDH1) were irreversibly
transitioned to the mesenchymal state. HCC827 cells transduced with lentiviral shRNA
against non-target served as control (HCC827 shNT). We observed that canonical
27
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epithelial cell marker E-Cadherin is significantly downregulated whereas canonical
mesenchymal cell marker N-Cadherin is upregulated in HCC827 shEGFR and HCC827
shCDH1 cells as compared to control HCC827 shNT cells (Figure 1B).
Mesenchymal-like HCC827 cells with constitutive EGFR or E-Cadherin knockdown
are resistant to EGFR tyrosine kinase inhibitor gefitinib. NSCLC cells that display
mesenchymal phenotype are resistant to EGFR TKI (34, 48). To determine if HCC827
cells with mesenchymal phenotype are resistance to EGFR TKI, HCC827 shNT,
HCC827 shEGFR and HCC827 shCDH1 cells were subjected to cell viability assay with
EGFR TKI- gefitinib for 72 hours. As shown in Figure 1A, epithelial HCC827 shNT cells
are exquisitely sensitive to gefitinib with the IC50 0.008 µM, while mesenchymal
HCC827 shEGFR and HCC827 shCDH1 cells were resistant to gefitinib with the IC50
1.35 µM and 0.24 µM respectively. The IC50 of HCC827 shEGFR and HCC827 shCDH1
cells to gefitinib increase more than 30 fold. In addition, we challenged the cells with
DMSO or 1 µM gefitinib for 48 hours. The cells were lysed at the end of 48 hour
treatment and lysates were subjected to Western blot with the antibodies indicated
(Figure 1B and1C). Exposure of HCC827 shEGFR to gefitinib did not promote PARP
cleavage and exposure of HCC827 shCDH1 cells to gefitinib promoted resulted in
decreased level of the PARP cleavage, which is a late apoptosis marker (104), as
compared to the control HCC87 shNT cells (Figure 1B). EGFR downstream signaling
pathways, PI3K and MAPK, are critical for cell survival and proliferation in EGFR mutant
NSCLC (22) and cells sensitive to EGFR TKI are characterized with remarkable downregulation of phosphorylated AKT (28, 29). Gefitinib treatment effectively inhibited
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activity of EGFR (Figure 1C) in HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1
cells. We observed remarkably decreased phosphorylation of AKT, ERK in HCC827
shNT cells (Figure 1C) which indicated that gefitinb treatment effectively depleted the
downstream signaling in control cells. In contrast, phosphorylating AKT and ERK were
maintained in HCC827 shEGFR cells after gefitinib treatment. Although gefitinib
effectively inhibit the phosphorylating ERK, we observed the maintained level of
phosphorylating AKT in HCC827 shCDH1 cells (Figure 1C). Our observation indicates
that in mesenchymal like HCC827 cells, when the activity of EGFR is completely
inhibited, cells sustained their downstream signaling pathway.
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Figure 1. Mesenchymal-like HCC827 cells with constitutive EGFR knockdown or ECadherin knockdown are resistant to EGFR TKI gefitinib. A, Exponentially growing
HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells were treated with
indicated concentration of gefitinib for 72 hours in duplicate and cell viability were
accessed using Cell Counting Kit-8. The viability of each sample was normalized to that
of DMSO-treated cells. Points, average of normalized values for experiments in
duplicates; error bars, SD. B, Exponentially growing HCC827 shNT, HCC827 shEGFR
and HCC827 shCDH1 cells were treated with 1µM control DMSO (-) or gefitinib (+) for
48hrs and lysates were subjected to Western blot with indicated antibodies. HCC827
shEGFR and HCC827 shCDH1 cells are mesenchymal phenotype with downregulation
of E-Cadherin and upregulation of N-Cadherin expression and resistant to gefitinib
treatment as evidenced by no or significantly reduced PARP cleavage. C, Exponentially
growing HCC827 shNT, HCC827sh EGFR and HCC827 shCDH1 cells were treated with
1µM control DMSO (-) or gefitinib (+) for 48hrs and lysates were subjected to Western
blot with indicated antibodies. Gefitinib treatment promoted depletion of phospho-EGFR,
phospho-AKT and phospho-ERK in HCC827 shNT cells. In contrast, mesenchymal
HCC827 shEGFR and HCC827 shCDH1 cells are resistant to gefitinib and EGFR
inhibition failed to completely inhibit phospho-AKT.

Part I: Tyrosine receptor kinase AXL
EGFR TKI resistant mesenchymal like HCC827 shEGFR and HCC827 shCDH1 cells
are insensitive to AXL inhibition and AXL inhibition does not restore their gefitinib
sensitivity. Recently, published studies indicate that upregulation of receptor tyrosine
kinase AXL replaced the function of EGFR and sustained PI3K signaling pathway in
EGFR TKI resistant NSCLC cells with mesenchymal phenotype when the activity of
EGFR is completely inhibited (74, 79). In order to quickly determine if the survival of
mesenchymal like HCC827 cells are dependent on AXL activation, we treated the cells
with an inhibitor of AXL alone or in combination with EGFR inhibition and determined
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percent control viability of the cells after 72 hours of drug treatment. Of note, there was
no potent and selective AXL inhibitor at the time when the study was carried out. XL-184
is a MET inhibitor which also inhibits AXL receptor with low concentration (7 nM) (105).
Extremely high concentration of XL-184 was required to compromised the cell viability of
HCC827 shNT, HCC827 shEGFR or HCC827 shCDH1 cells. In line with the previous
observation, HCC827 shEGFR and HCC827 shCDH1 cells increase their resistance to
gefitinib more than 17 fold with the IC50 2.4 µM and 0.14 µM, respectively. In contrast,
HCC827 shNT cells were sensitive to the gefitinib treatment with the IC50 0.008 µM. In
addition, XL184 did not restore gefitinib sensitivity in HCC827 shEGFR and HCC827
shCDH1 cells (Figure 2).
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Figure 2. AXL inhibition does not restore gefitinib sensitivity in EGFR TKI resistant
mesenchymal-like HCC827 cells with constitutive EGFR knockdown or E-Cadherin
knockdown. Exponentially growing HCC827 shNT, HCC827 shEGFR and HCC827
shCDH1 cells were treated with indicated concentrations of gefitinib, XL-184 or
combination of gefitinib and XL-184at ratio 1:1 for 72 hours in duplicate and cell viability
were accessed using Cell Counting Kit-8. The viability of each cell was normalized to
that of DMSO-treated cell. Points, average of normalized values for experiments in
duplicates; error bars, SD.

None of the 42 receptor tyrosine kinases listed in the RTK array seem to be driver
of EGFR TKI resistant HCC827 shEGFR and HCC827 shCDH1 cells with
mesenchymal phenotype. The data from Figure 1C showed the persistence of
phospho- AKT when the inhibition of EGFR activity was completed in the mesenchymallike HCC827 cells, and raised the possibility that AXL or any other potential receptor
tyrosine kinase was activated to offset the function of EGFR. To address this possibility,
we performed profiling of phospho-receptor tyrosine kinase (RTK) array in HCC827
shNT, HCC827 shEGFR and HCC827 shCDH1 cells with or without EGFR TKI
treatment. 42 receptor tyrosine kinases including AXL and other known receptors linked
to drug resistance in EGFR mutant NSCLC were tested. EGFR TKI treatment completely
inhibited phosphorylation of EGFR and the analysis did not identify the activation of any
RTK in mesenchymal-like HCC827 cells (Figure 3).
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Figure 3. Analysis using RTK array demonstrates no RTKs are activated in
mesenchymal-like EGFR TKIs resistant HCC827 cells upon gefitinib treatment.
Lysates from HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with
either DMSO or 1µM gefitinib for 24 hours were subjected to profiling of active RTKsusing RTK array that detects 42 phosphorylated RTKs. In each array, RTK is assayed in
duplicates. The dark dots represent activated RTKs. Right figure are made by Dr.
Shimamura.

AXL is upregulated in EGFR TKI resistant HCC827 shEGFR and HCC827 shCDH1
cells with mesenchymal phenotype; however its activity is dependent on the
activity of EGFR. Considering the limited sensitivity of RTK array, we confirmed
expression and activation levels of AXL in HCC827 shEGFR and HCC827 shCDH1 cells
treated with or without gefitinib by Western blot. We observed higher levels of AXL in
HCC827 shEGFR and HCC827 shCDH1 cells. However, gefitinib reduced AXL
phosphorylation (Figure 4), suggesting that AXL might be activated by EGFR-mediated
trans-phosphorylation and AXL activity was dependent on the activation of EGFR. This
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makes AXL less likely confer resistance to EGFR TKI treatment in mesenchymal-like
HCC827 cells.

Figure 4. EGFR inactivation downregulates AXL phosphorylation in mesenchymallike HCC827 cells with constitutive EGFR or E-Cadherin knockdown. Exponentially
growing HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells were treated with
DMSO or 1µM gefitinib for 48hrs and lysates were subjected to Western blot with
indicated antibodies. Note that AXL is overexpressed and activated in HCC827 shEGFR
and HCC827 shCDH1 cells; however, the phosphorylation of AXL is decreased upon
treatment of HCC827 shEGFR and HCC827 shCDH1 cells with gefitinib. Expression of
AXL/p-AXL indicated as 138kDa
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AXL depletion neither induces cell apoptosis nor resensitizes HCC827 shEGFR or
HCC827 shCDH1 cells to gefitinib. To further explore the role of AXL in acquired
EGFR TKI resistance in HCC827 shEGFR and HCC827 shCDH1 cells and to avoid offtarget effect of XL-184, we transfected HCC827 shNT, HCC827 shEGFR and HCC827
shCDH1 cells with siRNA coding for non-target or AXL and following either treated the
cells with DMSO or gefitinib. In line with what we observed before, gefitinib induced the
cell apoptosis in control HCC827 shNT cells with increased PARP cleavage. However,
AXL depletion alone or in combination with gefitnib did not promote cell apoptosis in
HCC827 shEGFR or HCC827 shCDH1 cells as evidenced by no PARP cleavage (Figure
5).
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Figure 5. AXL depletion alone or in combination with EGFR TKI do not induce
apoptosis in mesenchymal-like EGFR TKI resistant HCC827 cells with constitutive
EGFR or E-Cadherin knockdown. HCC827 shNT, HCC827 shEGFR and HCC827
shCDH1 cells were transfected with control siRNA (-) or siRNA targeting AXL (+).
Transfected cells were maintained in growth medium supplemented with 5% FBS.
48hours post-transfection, cells were then treated with DMSO (-) or 500nM gefitinib (+)
for additional 24 hours. Then the whole cell lysates were collected and subjected to
Western blot. Neither depletion of AXL alone nor combination of AXL depletion and
EGFR inhibition promotes PARP cleavage in HCC827 shEGFR and HCC827 shCDH1
cells. Expression of AXL/p-AXL indicated as 138kDa.

Part II: Chemokine receptor CXCR7
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CXCR7 is commonly upregulated in mesenchymal- like HCC827 cells. Since we
eliminated the possibility of AXL as an oncogenic driver replacing the function of EGFR
in mesenchymal like HCC827 cells, in order to elucidate other possible candidates that
confer EGFR TKI resistance, Dr. Shimamura performed comparative marker selection
(CMS) for mesenchymal like HCC827 cells and parental HCC827 cells. Genes which are
exclusively upregulated more than 3-fold in mesenchymal like HCC827 cells but not
HCC827 parental cells were captured (Figure 6). Of note, besides HCC827 shEGFR and
HCC827 shCDH1 cells, our lab also generated mesenchymal like HCC827 cells by
chronically exposing the cells to TGF-β which is a potent inducer of EMTin various
epithelial cells (101). 49 genes are commonly upregulated in mesenchymal like HCC827
cells as compared to parental HCC827 cells including chemokine receptor CXCR7.
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Figure 6. 49 unique genes commonly upregulated in the mesenchymal-like
HCC827 cells. Comparative marker selection (CMS) was performed to identify genes
uniquely upregulated in each mesenchymal-like HCC827 cells. Genes upregulated more
than 3 fold over control at 95% confidence interval was identified for each mesenchymallike cells. 49 unique genes were found commonly upregulated in HCC827 TGF-β,
HCC827 shEGFR and HCC827 shCDH1 cells. Figure was provided by Dr. Shimamura.

CXCR7 is overexpressed in HCC827 shCDH1 cells. In order to confirm the CXCR7
expression level identified in gene expression profiling, we performed RT-PCR to
quantify the amount of mRNA of CXCR7 in HCC827 shNT, HCC827 shEGFR and
HCC827 shCDH1 cells. Total RNA was isolated and analyzed for CXCR7 transcript in
HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with DMSO or
gefitinib. CXCR7 was significantly enhanced in EGFR TKI resistant mesenchymal like
HCC827 shCDH1 cells as compared to the control HCC827 shNT cells. Acute gefitinib
treatment increased the level of CXCR7 in all HCC827 shNT, HCC827 shEGFR and
HCC827 shCDH1 cells (Figure 7A). CXCR7 overexpression in mesenchymal like
HCC827 shCDH1 cells was also detected in Western blot with DMSO or gefitinib
treatment (Figure 7B).

39

B

Relative CXCR7 mRNA

A

Figure 7. CXCR7 is overexpressed in HCC827 cells with constitutive E-Cadherin
knockdown. A, Quantitative RT-PCR analysis of CXCR7 transcript induction in HCC827
shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with DMSO or gefitinib for
24 hours. Total mRNA was extracted from HCC827shNT, HCC827 shEGFR and
HCC827 shCDH1 cells treated with DMSO or gefitinib. Each sample was amplified in
duplicate for quantification of CXCR7 and GusB transcripts. Mean expression level of
CXCR7 was analyzed by relative quantitation using ΔΔCt method and normalization to
GusB. Each bar represents the relative quantity of mRNA in one sample. Error bars, SD.
CXCR7 transcripts were abundantly expressed in HCC827 with constitutively ECadherin knockdown. B, To confirm that increase in the expression of CXCR7
transcripts leads to the overexpression of CXCR7 protein, exponentially growing cells
were treated with DMSO or 1µM gefitinib for 24 hours and lysates were subjected to
Western blot with indicated antibodies. CXCR7 in HCC827 cells with constitutive ECadherin knockdown is higher compare to the HCC827 shNT cells. Expression of
CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translational
ubiqutination type)
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Ectopic CXCR7-V5 overexpression in HCC827 NSCLC cells. To systematically
assess the role of CXCR7 in EGFR TKI resistant NSCLC cells, we ectopically
overexpressed CXCR7 tagged with V5 in HCC827 cells (Figure 8).

Figure 8. CXCR7-V5 was ectopically overexpressed in HCC827 cells. HCC827 cells
were transduced with lentivirus coding for V5 tagged CXCR7 (CXCR7-V5) expression
vectors. HCC827 cells transduced with lentivirus coding for GFP expression vector were
used as a control. Cell lysates were made from exponentially growing HCC827 GFP
cells or HCC827 CXCR7-V5 cells and the lysates were subjected to Western blot with
antibodies against CXCR7, V5 tag and control β-Actin. CXCR7 and V5 overexpression
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are confirmed in the HCC827 CXCR7-V5 cells. Expression of CXCR7 protein indicated
as 42 kDa (immature type) and 52 kDa (post-translational ubiqutination type)

Ectopic CXCR7 overexpression in HCC827 cells promotes mesenchymal
phenotype. Unexpectedly, we observed the mesenchymal-like morphological change
after ectopic CXCR7-V5 overexpression in HCC827 cells. HCC827 CXCR7-V5 cells
exhibited spindle, elongated and scattered mesenchymal-like morphology while the
control HCC827 GFP exhibited cobblestone and patching morphology (Figure 9). Since
cells that transition into a mesenchymal state undergo cell canonical markers change,
we investigated the canonical epithelial and mesenchymal markers for HCC827 GFP
and HCC827 CXCR7-V5 cells. In consistent with what we observed in morphological
changes, we detected that canonical epithelial marker E-Cadherin was significantly
downregulated while canonical mesenchymal marker vimentin was upregulated in
HCC827 CXCR7-V5 as compared to HCC827 GFP cells (Figure 10).
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Figure 9. Phenotype changes in HCC827 cells with ectopic overexpression of
CXCR7-V5. Bright field microscopic images (10x magnification) demonstrates ectopic
expression of CXCR7-V5 in HCC827 promotes elongated mesenchymal-like cell
morphology. HCC827 GFP cells show epithelial morphology which are cobblestone and
flattend wheras HCC827 CXCR7-V5 cells show mesenchymal-like morphology which
are scattered and elongated.
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Figure 10. Ectopic CXCR7-V5 overexpression in HCC827 cells promotes induction
of mesenchymal-like phenotype. Whole cell lysates were made from exponentially
growing HCC827 GFP or HCC827 CXCR7-V5 cells. The whole cell lysates were
subjected to Western blot using indicated antibodies. HCC827 CXCR7-V5 cells display
mesenchymal-like transition demonstrated by E-Cadherin downregulation and Vimentin
upregulation compared to HCC827 GFP cells.

Ectopic CXCR7 overexpression in NCI-H1975 cells promotes mesenchymal
transition. In order to investigate if ectopic CXCR7 expression is sufficient to promote
epithelial to mesenchymal transition in other EGFR mutant NSCLC cells, we
overexpressed CXCR7 in NCI-H1975 cells which express L858R/T790M EGFR kinase
domain mutations and are sensitive to irreversible EGFR TKI. In consistent with what we
observed in HCC827 cells, ectopic CXCR7 overexpression in NCI-H1975 cells
significantly decreased the level of canonical epithelial marker E-Cadherin and
upregulated the canonical mesenchymal marker N-Cadherin (Figure 10). In addition, in
NCI-H1975 CXCR7-V5 cells, we observed upregulation of Twist and Snail which are
important transcription factors to induce mesenchymal phenotype in cultured cells (106)
(Figure 10).
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Figure 11. Ectopic overexpression of CXCR7 promotes mesenchymal phenotype
in NCI-H1975 cells. NCI-H1975 cells were transduced with lentivirus coding for LacZ or
CXCR7-V5 expression vectors. Cell lysates of NCIH1975 LacZ and NCI-H1975 CXCR7V5 cells were collected and subjected to the Western blot with antibodies against
CXCR7, V5 tag and canonical epithelial or mesenchymal cell markers. Expression of
CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translational
ubiqutination type).
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Ectopic CXCR7 overexpression is sufficient to confer EGFR TKI resistance in
HCC827 cells. Epithelial to mesenchymal transition has been reported to confer drug
resistance in EGFR mutant NSCLC (45, 56). Moreover, we hypothesized that HCC827
cells with ectopic CXCR7 overexpression attenuates their EGFR TKI sensitivity through
‘receptor switch’. To determine whether HCC827 CXCR7-V5 cells with mesenchymal
phenotype are resistant to EGFR TKI, HCC827, HCC827 GFP and HCC CXCR7-V5
cells were subjected to cell viability assay with gefitinib for 72 hours. By comparing IC50,
we observed that HCC827 CXCR7-V5 cells with mesenchymal phenotype were 14 times
resistant to gefitinib treatment as compared to control HCC827. We quantified
percentage apoptosis induced by gefitinib using Annexin V-FITC/PI double staining and
flow cytometric analysis. Data shown in Figure 13 shows that gefitinib treatment induced
apoptosis in 46% of control HCC827 LacZ cells. However, gefitinib treatment induced
apoptosis increased about 1 % of HCC827 CXCR7-V5 cells that is in different from
percent of apoptotic cells found in DMSO treated HCC827 CXCR7-V5 cells (3.42%). In
Western blot, gefitinib treatment induced significant increase in PARP cleavage in
control HCC827 GFP cells while same treatment failed to induce PARP cleavage in
HCC827 CXCR7-V5 cells (Figure 14). In addition, exposure of HCC827 GFP to gefitinib
resulted in significantly decreased level of phospho- AKT and phospho-ERK indicating
that gefitinib inhibited the downstream signaling in control cells. However, exposure of
HCC827 CXCR7-V5 to gefitinib resulted in decreased the level of phospho-ERK;
however, the level of phospho-AKT was maintained (Figure 14).
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Figure 12. Ectopic overexpression of CXCR7 attenuates the sensitivity of HCC827
cells to EGFR TKI. Exponentially growing HCC827, HCC827 GFP, HCC827 CXCR7-V5
cells were treated with indicated concentration of gefitinib for 72 hours in duplicates and
cell viability was assessed using Cell Counting Kit-8. The viability of each cell line was
normalized to that of DMSO-treated cell. Points, average of normalized values for
experiment in duplicates; error bars, SD. The table list calculated IC50 values against
gefitinib.
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Figure 13. Assessment of apoptosis by Annexin V-FITC/ PI double staning
demonstrates that gefitinib treatment does not compromise viability of cells
ectopically expressing CXCR7-V5. Quantification of flow cytometric analysis using
Annexin V-FITC and propidium iodide staining indicates that 48 hours of 1μM gefitinib
treatment does not induce apoptosis in CXCR7 overexpressing HCC827 cells. getinib
treatment induced almost10 fold more cell death in HCC827 LacZ cells (49.2%
apoptosis) when compared with DMSO treated HCC827 LacZ cells(5.98%) while there
was no change in percentage apoptosis in HCC827 CXCR7-V5 cells treated with
(4.68%) or without ( 3.42%) gefitinib. Right columns indicates average of normalized
percent Annexin positive cells for two independent experiments; error bars, SD.
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Figure 14. Geftinib treatment promotes significantly less PARP-cleavage in
HCC827 cells with CXCR7-V5 overexpression than in HCC827 GFP control cells.
HCC827 GFP and HCC827 CXCR7-V5 cells were treated with DMSO or indicated
concentration of gefitinib for 24 hours. The cells were lysed and the lysates were
subjected to Western blot using indicated antibodies. HCC827 GFP cells are sensitive to
gefitinib treatment as evidenced by the PARP cleavage and significant depletion of
phospho-AKT, phospho-ERK after gefitinib treatment. In contrast, exposure to gefitinib
does not promote PARP cleavage in HCC827 CXCR7-V5 cells and PI3K signal persists
despite the inhibition of EGFR as evidenced by phospho-AKT.
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CXCR7 depletion restores gefitinib sensitivity in HCC827 CXCR7-V5 cells. Our
observations with stable CXCR7 expression in HCC827 cells demonstrated that ectopic
CXCR7 expression confers EGFR TKI resistance in EGFR mutant NSCLC (Figure
12,13,14). To further confirm that CXCR7 is sufficient to confer resistance to EGFR TKI,
we depleted CXCR7 from HCC827 CXCR7-V5 cells to see if CXCR7 depletion would
resensitize the HCC827 CXCR7-V5 cells to gefitinib. We stably knocked down CXCR7
using lentiviral shRNA against CXCR7 in HCC827 CXCR7-V5 cells. CXCR7 was
effectively depleted by shCXCR7 in HCC827 CXCR7-V5 cells as indicated in Figure
15A. Exposure of HCC827 CXCR7-V5 cells with CXCR7 knockdown to gefitinib restored
the level of cell apoptosis marker- PARP cleavage while HCC827 CXCR7-V5 cells
transduced with shRNA against NT maintained the low level of PARP cleavage after
treated with gefitinib (Figure 15B). In addition, depletion of ectopic CXCR7 expression in
HCC827 CXCR7-V5 cells resulted in diminishing phospho-AKT and phosph-ERK after
gefitinib treatment which was the manner similar as HCC827 GFP cells treated with
gefitinib. In line with the previous observation, HCC827 CXCR7-V5 cells transduced with
shRNA against NT maintained PI3K and MAPK signaling after treated with gefitinib
(Figure 15C).
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Figure 15. EGFR TKI resistance in HCC827 cells by ectopic overexpression of
CXCR7 is reversible. A, HCC827 GFP (GFP) cells stably expressing non-target shRNA
(NT) were established and treated with DMSO (-) or 500nM gefitinib (+) for 48 hours.
HCC827 CXCR7-V5 (CXCR7-V5) cells stably expressing non-target shRNA (NT) or two
best shRNA sequence targeting CXCR7 (CXCR7-1 and CXCR7-2) were established and
treated with 1µM DMSO (-) or gefitinib (+) for 48 hours. Whole cell lysate were prepared
and the lysate were subjected to the Western blot using indicated antibodies. Expression
of CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translationally
modified type). B, Using the same lysates, Western blots with indicated antibodies were
performed to confirm inactivation of EGFR and PARP-cleavage by gefitinib treatment.
Note PARP-cleavage was not observed in gefitinib treated CXCR7-V5 overexpressing
cells (4th lane), whereas knockdown of CXCR7 in CXCR7-V5 overexpressing cells
restored sensitivity to gefitinib as evidenced by PARP-cleavage (lanes 6 and 8). C,
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Using the same lysates, Western blots with indicated antibodies were performed to
access PI3K and MAPK pathway activities by interrogating AKT (S473) and ERK (T202/
Y204), respectively. Representational figure from two independent experiments shown.

CXCR7 knockdown partially reverse mesenchymal HCC827 CXCR7-V5 to
epithelial. We observed stable CXCR7 overexpression in epithelial HCC827 cells
induced the mesenchymal-like transition in EGFR mutant NSCLC (Figure 9,10). EMT is
reported to be a reversible process (48) and CXCR7 knockdown reversed gefitinib
sensitivity in HCC827 CXCR7-V5 cells, therefore we next investigated if EMT induced by
ectopic CXCR7 overexpression in EGFR mutant NSCLC is also reversible. Depletion of
CXCR7 in HCC827 CXCR7-V5 cells did not induce an apparent phenotype change
when observed under microscope (data not shown). When investigated with Western
blot, we observed increased level of canonical epithelial cell marker, ZO1 and decreased
expression of canonical mesenchymal marker, Vimentin. However, the expression of ECadherin after CXCR7 knockdown did not change` (Figure 15). The results indicate that
CXCR7 depletion partially reverses HCC827 CXCR7-V5 to epithelial phenotype.

52

Figure 16. Depletion of CXCR7 partially restores epithelial phenotype. HCC827
GFP (GFP) cells and HCC827 CXCR7-V5 (CXCR7-V5) cells were transduced with
lentiviruses coding for non-target sequence (NT) or two best shRNA sequence targeting
CXCR7 (CXCR7-1 and CXCR7-2). Stable cell lines were established. Whole cell lysate
were prepared and the lysates were subjected to the Western blot using indicated
antibodies to interrogate canonical epithelial and mesenchymal markers. HSP90 serves
as loading control.

CHAPTER FOUR
DISCUSSION
NSCLC harboring activating EGFR kinase domain mutations is a unique subtype
of NSCLC. NSCLC patients haboring EGFR kinase domain mutations respond well to
EGFR TKI. However, the emergence of acquired resistance to EGFR TKI greatly limits
the efficiency of targeted therapy (24).
Besides the well-established resistant mechanisms including EGFR T790M
secondary mutation, and MET amplification mutation, 30 percent of the resistant
mechanisms remain elusive. Among these unknown resistant mechanisms, about half of
these resistant NSCLC present an evidence of EMT (45). However, it remains unclear
which components of EMT directly contribute to the EGFR TKI resistance. Based on the
mechanisms for known EGFR TKI acquired resistance, we hypothesized that EMT
program associates with the upregulation of the novel cellular signaling mechanisms that
the cell can depend on when EGFR activity is inhibited by EGFR TKI.
In order to study EGFR TKI resitant mechanisms in EGFR mutant NSCLC cells
with mesenchymal phenotype, we induced mesenchymal phenotype in HCC827 cells by
knocking down CDH1. We also made mesenchymal and EGFR TKI resistant HCC827
cells by stably expressing shRNA against EGFR. It has been reported that AXL is
overexpressed in mutant EGFR NSCLC cells with mesenchymal phenotype, therefore
AXL has been considered as a potential candidate to confer resistance to EGFR TKI
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through ‘receptor tyrosine kinase swith’ (74). In our study we observed the
overexpression of AXL in EGFR TKI resistant HCC827 shEGFR cells and HCC827
shCDH1 cells. Furthermore, our experimental results show that AXL phosphorylation is
dependent on EGFR activity (Figure 4) as inhibition of EGFR with gefitinib
dephosphorylated not only EGFR but also AXL. The results suggest that AXL activity
cannot compensate the loss of EGFR activity in our mesenchymal HCC827 shEGFR
and HCC827 shCDH1 cells. In addition, inhibition of AXL activity using XL-184 or
depletion of AXL using siRNA did not compromise cell viability or restore their gefitinib
sensitivity in HCC827 shEGFR and HCC827 shCDH1 clles (Figure 2,5). Our data
suggests that AXL is less likely to confer resistance to EGFR TKI in HCC827 cells with
mesenchymal phenotype. We speculated if overexpression of AXL is a biomarker of
mesenchymal phenotype rather than an oncogenic driver that replaces mutant EGFR.
In order to identify oncogenic driver for mesenchymal EGFR mutant HCC827
cells, Dr. Shimamura performed comparative marker selection (CMS) on differential
gene expression data for HCC827 shEGFR, HCC827 shCDH1 and HCC827 cells
chronically exposed to TGF-β. G-protein coupled receptor- CXCR7 is significantly
upregulated in mesenchymal-like HCC827 cells including HCC827 shEGFR, HCC827
shCDH1 and HCC827 cells chronically exposed to TGF-β (Figure 6). The subsequent
analysis of mRNA expression and Western blot confirmed the upregulation of CXCR7 in
the mesenchymal-like HCC827 cells (Figure 7). Of note, our collaborative laboratory at
Dana-Farber Cancer Institue generated genetically engineered mouse model haboring
EGFR kinase domain mutant NSCLC tumor and demonstrated that the induction of the
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mutant EGFR in type II clara cells induce lung adenocarcinoma. In the model,
adenocarcinoma with acquired resistance to EGFR TKI was observed upon 12 weeks of
continuous EGFR TKI treatment. Histological analyses of the resistant tumors showed a
significant upregulation of CXCR7 expression and a significant upregulation of canonical
mesenchymal markers (data not shown). Collective evidence lead us to further explore
the role of CXCR7 in EGFR mutant EGFR TKI resistant NSCLC cells.
The role of CXCR7 with respect to EGFR TKI resistance in EGFR mutant NSCLC
cells has never been reported. In order to establish the relationship between CXCR7 and
EGFR TKI resistance, we established an in vitro model that ectopically express V5tagged CXCR7 in EGFR mutant HCC827 cells. We observed that ectopic CXCR7
overexpression attenuates EGFR TKI sensitivity in HCC827 cells (Figure 12, 13, 14). In
addition, we observed that AKT phosphorrylation was maintained after acute EGFR
inhibition by gefitinib treatment in HCC827 CXCR7 cells (Figure 14). Similarly, EGFR
inhibition did not attenuate AKT phosphorylation in HCC827 CDH1 cells with
mesenchymal phenotype (Figure 1C). In NSCLC, AKT (S473) phosphorylation serves as
a biomarker of PI3K pathway activity (28, 29). A considerable number of literature has
sugguested that CXCR7 activates PI3K pathway through beta-arrestin (84, 95). To our
surprise, CXCR7 is sufficient to upregulate canonical mesenchymal markers and to
downregulate epithelial markers(Figure 10, 11). Importantly, depletion of the ectopically
expressed CXCR7 in HCC827 cells (HCC827 CXCR7-V5) resensitized the cells to
EGFR TKIs and partially restored epithelial phenotype (Figure 15, 16). The experiment
confirmed the notion that the ectopically expressed CXCR7 is responsible for the EGFR
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TKI resistance in HCC827 cells. We observed that CXCR7 depletion- induced a partial
phenotype revision in HCC827 CXCR7-V5 cells may suggest that CXCR7 induced
mesenchymal-like cells may activate varieties of autocrine signaling loops that may be
maintained even after CXCR7 is depleted. The activation of EMT programs involves a
series of transitions and a spectrum of multiple intermediated states lying between these
two endpoints (107). The epigenetic regulations of EMT describe the mechanisms that
impose cellular phenotype with covalent modification of DNA, specially the methylation
of certain DNA residues, as well as the gain of repressive histone modifications that form
DNA-associated nucleosomes (107). Therefore, it is possible that the reversibility of
EMT process requires comprehensive reprogramming of gene expression even though
the protein that initiates mesnchymal transition is depleted. These evidence may explain
why depletion of CXCR7 would not completely reverse the process of EMT.
While overexpression of CXCR7 in HCC827 cells was sufficient to promote EMT
and to confer EGFR TKI resistance, it remains elusive if ligand stimulation is involved in
the process. In general, the activation of CXCR7 requires the presence of its ligands
SDF-1α/ CXCL12 or ITAC/CXCL11 (82). Therefore it is speculated if CXCR7 can be self
activated without the presence of appropriate ligand if it is sufficiently overexpressed.
Alternatively, it is possible that ectopic expression of CXCR7 promotes the expression of
CXCR7 ligand to establish autocrine loop. Nontheless, further investigations to elucidate
CXCR7 activation mechanisms are necessary.
Although serval reports have shown that G protein coupled receptor promotes
EMT, there is no report demonstrating that CXCR7 promotes EMT and EGFR TKI
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resistance. Our observations may suggest a novel link between chemokine receptor
CXCR7 and EMT. However, the mechanisms by which CXCR7 induces EMT remain
elusive. Additionally, we observed CXCR7 induced upregulation of EMT transcription
factor Twist and Snail in H1975 cells (Figure 11) but not in HCC827 cells (data not
shown) which indicates that the mechanisms by which CXCR7 induces EMT may be cell
lineage specific.
Interestingly, we observed upregulation and phophorylation of AXL in HCC827
CXCR7-V5 cells (data not shown). However, in consistent with what we observed in
HCC827 shEGFR and HCC827 shCDH1 cells, gefitinib treatment of HCC827 CXCR7V5 cells resulted in decreased AXL phosphorylation and AXL inhibition or depletion by
siRNA did not restore gefitinib sensitivity in the cells (data not shown). This observation
suggests that AXL upregulation associates with epithelial to mesenchymal transition but
AXL activity is not sufficient to replace mutant EGFR activity in mutant EGFR mutant
NSCLC with mesenchymal phenotype.
The potential problem of our system with ectopic CXCR7-V5 overexpression in
HCC827 cells is that we did not confirm if CXCR7 is activated. Since CXCR7 is activated
by assocaition with β-arrestin, future studies with co-immunoprecipitation or Spell FRET
(FRET) is required to test if CXCR7 interacts with β-arrestin in HCC827 CXCR7-V5 cells.
Futher investigation revealed that HCC827 shCDH1 overexpress CXCR7 (Figure
7) while 42 major RTKs were not phosphorylated (Figure 3). Based on the result, we
hypothesized that CXCR7 activates PI3K pathway in HCC827 shCDH1 cells when they
are treated with EGFR TKI. In order to determine if CXCR7 is necessary to confer EGFR
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TKI resistance in HCC827 shCDH1 cells, we knockdown CXCR7 in EGFR TKI resistant
mesenchymal-like HCC827 shCDH1 cells using CXCR7- specific siRNA and determined
if we could restore their sensitivity to EGFR TKI in HCC827 shCDH1 cells. Unfortunately,
we were not able to effectively depleted CXCR7 using siRNA in HCC827 shCDH1 cells
(data not shown). Considering the possibility that siCXCR7 we purchased were not
effective to knockdown CXCR7, we also use lentiviral shRNA against CXCR7 in
HCC827 Snail-V5 cells that ectopically overexpress EMT-inducing transcription factor
Snail. HCC827 Snail-V5 cells exhibit mesenchymal phenotype and the cells are resistant
to EGFR TKI. The data suggested that CXCR7 knockdown restored the EGFR TKI
sensitivity of HCC827 Snail-V5 cell (data not shown). In conclusion, our data suggests
that CXCR7 is sufficient and necessary to confer EGFR TKI resistance in HCC827 cells.
Based on the data we have observed, we proposed that chronic EGFR TKI
treatment in EGFR mutant NSCLC promotes overexpression of CXCR7 and CXCR7
maintains survival and proliferation pathway when mutant EGFR is unable to activate the
pathways under the EGFR TKI treatment (Figure 16).
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Figure 17. A schematic diagram of a proposed mechanism for CXCR7- mediated
acuqired EGFR TKI resistance in EGFR mutant NSCLC. Our results suggest that
CXCR7 is overexpressed in EGFR mutant NSCLC with mesenchymal phenotype. The
activation of CXCR7 augument the mutant EGFR signaling when mutant EGFR receptor
is inhibited. CXCR7 signaling promotes cell survival, proliferation and mesenchymal
phenotype in EGFR TKI resistant EGFR mutant NSCLC cells.

In conclusion, we discovered that ectopic CXCR7 expression in EGFR-TKI
sensitive HCC827 and NCI-H1975 cells confers EGFR TKI resistance and induces the
mesenchymal phenotype. Taken together, our data suggests that CXCR7 might have its
potential therapeutic implications for preventing or overcoming EGFR TKI resistance in
EGFR mutant NSCLC patients with mesenchymal phenotype. Future studies will be
necessary will be necessary to determine if CXCR7 is an oncogene in NSCLC and the
mechanisms of CXCR7 upregulation in NSCLC with EGFR TKI resistance. The
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investigation will provide insights into the developing the therapeutic intervention of
CXCR7 mediated EGFR TKI resistance in EGFR mutant NSCLC.
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